831 related articles for article (PubMed ID: 15762770)
1. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs.
Zhou S; Yung Chan S; Cher Goh B; Chan E; Duan W; Huang M; McLeod HL
Clin Pharmacokinet; 2005; 44(3):279-304. PubMed ID: 15762770
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4.
Zhou S; Chan E; Lim LY; Boelsterli UA; Li SC; Wang J; Zhang Q; Huang M; Xu A
Curr Drug Metab; 2004 Oct; 5(5):415-42. PubMed ID: 15544435
[TBL] [Abstract][Full Text] [Related]
3. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4.
Zhou SF
Curr Drug Metab; 2008 May; 9(4):310-22. PubMed ID: 18473749
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.
Dresser GK; Spence JD; Bailey DG
Clin Pharmacokinet; 2000 Jan; 38(1):41-57. PubMed ID: 10668858
[TBL] [Abstract][Full Text] [Related]
5. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring.
Zhou SF; Xue CC; Yu XQ; Li C; Wang G
Ther Drug Monit; 2007 Dec; 29(6):687-710. PubMed ID: 18043468
[TBL] [Abstract][Full Text] [Related]
6. Automated screening with confirmation of mechanism-based inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2 in pooled human liver microsomes.
Lim HK; Duczak N; Brougham L; Elliot M; Patel K; Chan K
Drug Metab Dispos; 2005 Aug; 33(8):1211-9. PubMed ID: 15860655
[TBL] [Abstract][Full Text] [Related]
7. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
Cvetkovic RS; Goa KL
Drugs; 2003; 63(8):769-802. PubMed ID: 12662125
[TBL] [Abstract][Full Text] [Related]
8. Prediction of the effect of erythromycin, diltiazem, and their metabolites, alone and in combination, on CYP3A4 inhibition.
Zhang X; Jones DR; Hall SD
Drug Metab Dispos; 2009 Jan; 37(1):150-60. PubMed ID: 18854379
[TBL] [Abstract][Full Text] [Related]
9. Potential strategies for minimizing mechanism-based inhibition of cytochrome P450 3A4.
Zhou SF
Curr Pharm Des; 2008; 14(10):990-1000. PubMed ID: 18473851
[TBL] [Abstract][Full Text] [Related]
10. Resveratrol, a red wine constituent, is a mechanism-based inactivator of cytochrome P450 3A4.
Chan WK; Delucchi AB
Life Sci; 2000 Nov; 67(25):3103-12. PubMed ID: 11125847
[TBL] [Abstract][Full Text] [Related]
11. Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes.
Wen X; Wang JS; Neuvonen PJ; Backman JT
Eur J Clin Pharmacol; 2002 Jan; 57(11):799-804. PubMed ID: 11868802
[TBL] [Abstract][Full Text] [Related]
12. Prediction of time-dependent CYP3A4 drug-drug interactions by physiologically based pharmacokinetic modelling: impact of inactivation parameters and enzyme turnover.
Rowland Yeo K; Walsky RL; Jamei M; Rostami-Hodjegan A; Tucker GT
Eur J Pharm Sci; 2011 Jun; 43(3):160-73. PubMed ID: 21540107
[TBL] [Abstract][Full Text] [Related]
13. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects.
Mueck W; Kubitza D; Becka M
Br J Clin Pharmacol; 2013 Sep; 76(3):455-66. PubMed ID: 23305158
[TBL] [Abstract][Full Text] [Related]
14. Differences in the inhibition of cytochromes P450 3A4 and 3A5 by metabolite-inhibitor complex-forming drugs.
McConn DJ; Lin YS; Allen K; Kunze KL; Thummel KE
Drug Metab Dispos; 2004 Oct; 32(10):1083-91. PubMed ID: 15377640
[TBL] [Abstract][Full Text] [Related]
15. Imidazoacridinone antitumor agent C-1311 as a selective mechanism-based inactivator of human cytochrome P450 1A2 and 3A4 isoenzymes.
Potęga A; Fedejko-Kap B; Mazerska Z
Pharmacol Rep; 2016 Aug; 68(4):663-70. PubMed ID: 27110874
[TBL] [Abstract][Full Text] [Related]
16. An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation.
Mayhew BS; Jones DR; Hall SD
Drug Metab Dispos; 2000 Sep; 28(9):1031-7. PubMed ID: 10950845
[TBL] [Abstract][Full Text] [Related]
17. General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs.
Ohno Y; Hisaka A; Suzuki H
Clin Pharmacokinet; 2007; 46(8):681-96. PubMed ID: 17655375
[TBL] [Abstract][Full Text] [Related]
18. Progress curve mechanistic modeling approach for assessing time-dependent inhibition of CYP3A4.
Burt HJ; Pertinez H; Säll C; Collins C; Hyland R; Houston JB; Galetin A
Drug Metab Dispos; 2012 Sep; 40(9):1658-67. PubMed ID: 22621802
[TBL] [Abstract][Full Text] [Related]
19. Biotransformation of parathion in human liver: participation of CYP3A4 and its inactivation during microsomal parathion oxidation.
Butler AM; Murray M
J Pharmacol Exp Ther; 1997 Feb; 280(2):966-73. PubMed ID: 9023313
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes and management of mechanism-based inhibition of cytochrome P450 3A4.
Zhou S; Chan E; Li X; Huang M
Ther Clin Risk Manag; 2005 Mar; 1(1):3-13. PubMed ID: 18360537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
